Lancet
-
Retraction Of Publication
Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19.
-
Randomized Controlled Trial Multicenter Study
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and reduced quality of life. There is no approved treatment for vitiligo repigmentation and current off-label therapies have limited efficacy, emphasising the need for improved treatment options. We investigated the therapeutic potential of ruxolitinib cream in patients with vitiligo and report the efficacy and safety results up to 52 weeks of double-blind treatment. ⋯ Incyte.
-
Some studies, mainly from high-income countries (HICs), report that women receive less care (investigations and treatments) for cardiovascular disease than do men and might have a higher risk of death. However, very few studies systematically report risk factors, use of primary or secondary prevention medications, incidence of cardiovascular disease, or death in populations drawn from the community. Given that most cardiovascular disease occurs in low-income and middle-income countries (LMICs), there is a need for comprehensive information comparing treatments and outcomes between women and men in HICs, middle-income countries, and low-income countries from community-based population studies. ⋯ Full funding sources are listed at the end of the paper (see Acknowledgments).